Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (ALL) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dalbavancin (acute bacterial infections of the skin and the soft tissue, = 3 months) - Assessment according to § 35a (1c), Social Code Book (SGB) V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (tuberculosis) – Assessment according to § 35a (1), Sentence 11, Social Code Book (SGB) V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Teclistamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nonacog beta pegol (haemophilia B, children < 12 years) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Penile traction therapy for induratio penis plastica]
2023	NIHR Health Technology Assessment programme	Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023	Health Information and Quality Authority (HIQA)	An overview of national approaches to stockpiling of medical countermeasures for public health emergencies
2023	Health Information and Quality Authority (HIQA)	Ultra-hypofractionated adjuvant radiotherapy for breast cancer: evidence synthesis to support a generic justification decision
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2023	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Cost-utility analysis of universal neonatal screening for critical congenital heart disease based on pulsioximetry in Spain]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023	WorkSafeBC	Low intensity pulsed ultrasound (LIPUS) for preventing fractures
2023	WorkSafeBC	Efficacy of eye movement desensitization and reprocessing (EMDR) as treatment for major depression
2023	WorkSafeBC	Firefighting and polycythemia vera
2023	WorkSafeBC	HEPA filters and nanomaterials
2023	WorkSafeBC	Hemorrhoids and heavy lifting
2023	WorkSafeBC	Association between wearing orthosis and developing metatarsal stress fractures
2023	WorkSafeBC	Causal association between firefighting and hypersensitivity pneumonitis
2023	Canary Health Service	[Cost-effectiveness of newborn screening for tyrosinemia type I (update)]
2023	NIHR Health Services and Delivery Research programme	Remote monitoring for long-term physical health conditions: an evidence and gap map
2023	NIHR Health Services and Delivery Research programme	What factors are associated with informal carers’ psychological morbidity during end-of-life home care? A systematic review and thematic synthesis of observational quantitative studies
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic-laden bone cement
2023	NIHR Health Technology Assessment programme	Pragmatic randomised controlled trial of guided self-help versus individual cognitive behavioural therapy with a trauma focus for post-traumatic stress disorder (RAPID)
2023	NIHR Health Technology Assessment programme	Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit–risk assessment: the BRAINS study including expert workshop
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Medication review and reconciliation in the outpatient setting
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2023	Canary Health Service	[Evaluation of the lung cancer screening program]
2023	Canary Health Service	[Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2023	Canary Health Service	[Effectiveness and safety of bioelectrical stimulation techniques in fibromyalgia: systematic review]
2023	Canary Health Service	[Evaluation of patient involvement in health technology assessment]
2023	Norwegian Institute of Public Health (NIPH)	[Mupirocin nasal ointment as infection prevention prophylaxis prior to orthopaedic prosthesis surgery: a rapid health technology assessment]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Biologic drugs for severe asthma
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Routine dental polishing for oral health
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intraocular lenses for cataract surgery
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Refractive laser surgery for vision conditions
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Buprenorphine naloxone film versus tablets for opioid use disorder
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Case carts in surgical settings
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti–vascular endothelial growth factor drugs for age-related macular degeneration
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Point of care ultrasound for guided central venous catheter insertion
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	IV acetaminophen for acute pain in emergency departments
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Semaglutide 2 mg for type 2 diabetes
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Midline and extended dwell catheters for IV antibiotics
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Radiofrequency ablation for chronic knee, hip, and shoulder pain
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct-acting antivirals for pediatric chronic hepatitis C virus infection
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin for short stature
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-sterile glove use
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Early intervention programs for adolescents and young adults with eating disorders
2023	Canary Health Service	[Software applications for prevention and intervention in people at risk of suicide: effectiveness, safety and cost-effectiveness]
2023	NIHR Health Services and Delivery Research programme	The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Embolization vs. conservative management for spontaneous abdominal or pelvic hemorrhage
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effective analysis evaluation of galcanezumab (Emgality)]
2023	NIHR Health Services and Delivery Research programme	Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	NIHR Health Technology Assessment programme	Exercise therapy for tendinopathy: a mixed-methods evidence synthesis exploring feasibility, acceptability and effectiveness
2023	NIHR Health Technology Assessment programme	Posterior cervical foraminotomy versus anterior cervical discectomy for cervical brachialgia: the FORVAD RCT
2023	NIHR Health and Social Care Delivery Program	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	NIHR Health Technology Assessment programme	Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2023	NIHR Health Technology Assessment programme	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023	NIHR Health Technology Assessment programme	Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study
2023	NIHR Health Technology Assessment programme	Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
2023	NIHR Health Services and Delivery Research programme	Rapid evaluation of the Special Measures for Quality and challenged provider regimes: a mixed-methods study
2023	Norwegian Institute of Public Health (NIPH)	[Portable ECG equipment for the diagnosis of atrial fibrillation in the specialist health care: rapid HTA - scoping review]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[PICC line insertion by navigation system and confirmation of the catheter tip by intracavitary electrocardiogram]
2023	NIHR Health Services and Delivery Research programme	Reducing unplanned hospital admissions from care homes: a systematic review
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Emergency department overcrowding in Canada: an update
2023	Health Information and Quality Authority (HIQA)	Overview of multiplex antigen near-patient tests for acute respiratory infections
2023	NIHR Health Services and Delivery Research programme	Involving carer advisors in evidence synthesis to improve carers’ mental health during end-of-life home care: co-production during COVID-19 remote working
2023	Health Sciences Institute in Aragon (IACS)	[Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: gene panel for the identification of myeloid mutations by NGS ‒ evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Depression”]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “Coronary heart disease”]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab and teriflunomide for the treatment of adult patients with highly active relapsing remitting multiple sclerosis]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V]